Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG +3.76%41 Median PS Value is $0.52 as of Aug. 20, 2026, which is 59% below its 10-year median of 1.28. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 90 Medical Diagnostics & Research companies, Interpace Biosciences ranks worse than 95.56% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Interpace Biosciences's Median PS Value or its related term are showing as below:
IDXG'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4 Med: 1.28 Max: 3.27
Current: 3.13
During the past 13 years, the highest Price to Median PS Value of Interpace Biosciences was 3.27. The lowest was 0.40. And the median was 1.28.
IDXG's Price-to-Median-PS-Value is ranked worse than 95.56% of 90
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.9
vs IDXG: 3.13
Interpace Biosciences (OTCPK:IDXG) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Interpace Biosciences's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.629
/
0.52
=
3.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences Median PS Value Related Terms
Interpace Biosciences Median PS Value Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDXG vs PRPO, ADVB, BIOQ: Median PS Value Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.3988.
Interpace Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.304.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXG) has a Median PS Value of $0.52 as of Aug. 20, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Interpace Biosciences and its competitors. This is 59% below median its historical median of 1.28. Over the past decade, Interpace Biosciences' Median PS Value has ranged from 0.40 to 3.27. According to the industry distribution chart, Interpace Biosciences ranks #86 out of 90 companies in the Medical Diagnostics & Research industry, placing it in the top 95.6%.
Is Interpace Biosciences' Median PS Value too high?
Interpace Biosciences' current Median PS Value of $0.52 is 59% below median its 10-year median of 1.28. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 3.27. The Medical Diagnostics & Research industry median Median PS Value is 0.90. Interpace Biosciences' value of $0.52 is 42.2% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #86 out of 90 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Median PS Value compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #86 out of 90 companies for Median PS Value. This places Interpace Biosciences in the lower half of its industry. The industry median Median PS Value is 0.90. Interpace Biosciences' value of $0.52 is 42.2% below this benchmark. Historically, Interpace Biosciences' own Median PS Value has ranged from 0.40 to 3.27 over the past decade. While the company's 10-year median is 1.28 vs. the industry median of 0.90, Interpace Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.90, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current Median PS Value of $0.52 is 42.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current Median PS Value is $0.52, which is 59% below median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.63 — trading 714.5% above its estimated fair value. The current Median PS Value is $0.52, which is 59% below median its 10-year median of 1.28 and 42.2% below the Medical Diagnostics & Research industry median of 0.90. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current Median PS Value is $0.52 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.63 is trading 714.5% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
Median PS Value: $0.52 (59% below median its 10-year median of 1.28)
GF Value™: $0.20 vs. price of $1.63 (714.5% above fair value)
Industry Position: 42.2% below the Medical Diagnostics & Research median (#86 of 90)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
